Page 3 - Membrane Type News Today

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $21.17, but opened at $20.71. Bicycle Therapeutics shares last traded at $20.70, with a volume of 2,398 shares changing hands. Analysts Set New Price Targets Several analysts have recently weighed in […]

Logos Global Management LP cut its holdings in Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) by 47.7% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 750,000 shares of the company’s stock after selling 685,000 shares during the period. Bicycle Therapeutics comprises approximately 2.3% of Logos Global […]

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) dropped 2.7% on Wednesday . The stock traded as low as $23.17 and last traded at $23.20. Approximately 17,700 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 272,389 shares. The stock had previously closed at $23.85. Wall […]

Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) was the recipient of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 3,740,000 shares, a decline of 13.2% from the July 15th total of 4,310,000 shares. Based on an average daily volume of 223,800 shares, […]

Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nine analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month price objective […]

Morgan Stanley restated their equal weight rating on shares of Bicycle Therapeutics (NASDAQ:BCYC – Free Report) in a report issued on Friday morning, Benzinga reports. The brokerage currently has a $42.00 target price on the stock. A number of other equities analysts have also commented on the stock. HC Wainwright reissued a buy rating and […]

Bicycle Therapeutics (NASDAQ:BCYC – Free Report) had its price target reduced by JMP Securities from $46.00 to $44.00 in a research report released on Friday, Marketbeat Ratings reports. They currently have an outperform rating on the stock. Separately, EF Hutton Acquisition Co. I reiterated a buy rating and set a $55.00 price target on shares […]

HC Wainwright reiterated their buy rating on shares of Bicycle Therapeutics (NASDAQ:BCYC – Free Report) in a report published on Friday morning, Benzinga reports. They currently have a $57.00 price objective on the stock. BCYC has been the topic of a number of other reports. EF Hutton Acquisition Co. I reiterated a buy rating and […]

Bicycle Therapeutics (NASDAQ:BCYC – Free Report) had its target price cut by Needham & Company LLC from $48.00 to $46.00 in a research report sent to investors on Friday morning, Benzinga reports. They currently have a buy rating on the stock. A number of other equities research analysts have also issued reports on the stock. […]

Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) CEO Kevin Lee sold 1,498 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $25.10, for a total value of $37,599.80. Following the completion of the transaction, the chief executive officer now owns 323,601 […]